Is there a difference in clinical behavior between urothelial carcinoma of the upper urinary tract and that of the lower urinary tract? What is the risk of developing tumors in the contralateral and lower urinary tracts in patients presenting initially with an upper urinary tract cancer? Conversely, what is the risk of developing an upper urinary tract tumor in patients who initially present with a lower urinary tract tumor?


Urothelial neoplasms involving the upper urinary tract are uncommon, accounting for about 5% of primary urothelial neoplasms. Unlike tumors involving the lower urinary tract (mostly urinary bladder), more than 50% of them are of high grade and high stage (pT2 or higher) and typically require radical surgery such as nephrectomy or ureterectomy with or without nephrectomy. The risk of developing carcinoma in the contralateral kidney is 1%–3%.The projected incidence of a tumor in the contralateral kidney rises progressively from 2.7% to 6.5% during a follow-up from 5 years to 15 years, respectively. The incidence of bladder carcinoma subsequent to an upper tract carcinoma ranges from 9% to 48%. Bladder cancer is also significantly more common among patients with bilateral upper tract cancer. This high risk is probably due to both spreading of the original cancer and field changes (new cancer). For patients presenting with bladder cancer, the risk for developing upper tract cancer is 1%–4%.


Bladder Cancer Bladder Tumor Renal Pelvis Transitional Cell Carcinoma Urothelial Carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Murphy WM, Beckwith JB, Farrow GM (1994) Tumors of the kidney, bladder, and related urinary structures. Fascicle 11, 3rd series. In: Rosai J, Sobin LH (eds) Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, DC, pp 313–321.Google Scholar
  2. 2.
    Genega P, Vogelzang NJ, Randazzo R, Sener S, Chmiel J, Fremgen A, Sylvester J (1992) Renal pelvic cancer: a review of 611 patients treated in Illinois 1975–1985, 1992. Urology 40: 393–399.CrossRefGoogle Scholar
  3. 3.
    Guinan P, Chmiel J, Vogelzang NJ, Fremgen A, Randazzo R, Sylvester J, Sener S (1992) Renal pelvic cancer: a review of 611 patients treated in Illinois 1975–1985. Urology 40: 393–399.PubMedCrossRefGoogle Scholar
  4. 4.
    Melamed MR, Reuter VE (1993) Pathology and staging of urothelial tumors of the kidney and ureter. Urol Clin North Am 20: 333–347.PubMedGoogle Scholar
  5. 5.
    Nocks BN, Heney NM, Daly JJ, Perrone TA, Groffin PP, Prout GR Jr (1982) Transitional cell carcinoma of renal pelvis. Urology 19: 472–477.PubMedCrossRefGoogle Scholar
  6. 6.
    Dudak SC, Soloway MS, Neulander EZ (2000) Management of upper tract transitional cell carcinoma: surgical management. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds) Comprehensive text-book of genitourinary oncology. Lippincott Williams & Wilkins, Philadelphia, pp 367–376.Google Scholar
  7. 7.
    Olgac S, Mazmdar M, Dalbagni G, Reuter VE (2004) Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol 28: 1545–1552.PubMedCrossRefGoogle Scholar
  8. 8.
    Anonymous (2002) Renal pelvis and ureter. In: Greene FL, Page DL, Fleming ID, Fritz AG, Blech CM, Haller DG, Morrow M (eds) AJCC cancer staging manual. Springer-Verlag, New York, pp 329–331.Google Scholar
  9. 9.
    Bloom NA, Vidone RA, Lytton B (1970) Primary carcinoma of the ureter: a report of 102 new cases. J Urol 103: 590–598.PubMedGoogle Scholar
  10. 10.
    Batata MA, Whitmore WF, Hilaris BS, Tokita N, Grabstald H (1975) Primary carcinoma of the ureter: a prognostic study. Cancer 35: 1626–1632.PubMedCrossRefGoogle Scholar
  11. 11.
    Heney NM, Nocks BN, Daly JJ, Blitzer PH, Parkhurst EC (1981) Prognostic factors in carcinoma of the ureter. J Urol 125: 632–636.PubMedGoogle Scholar
  12. 12.
    Reuter VE (2004) The urothelial tract: renal pelvis, ureter, urinary bladder, and urethra. In: Mills SE (ed) Sternberg’s Diagnostic Surgical Pathology. Lippincott Williams & Wilkins, Philadelphia, pp 2035–2081.Google Scholar
  13. 13.
    Knowles MA (2001) What we could do now: molecular pathology of bladder cancer. Mol Pathol 54: 215–221.PubMedCrossRefGoogle Scholar
  14. 14.
    Huffman JL (2000) Management of upper tract transitional cell carcinomas: endoscopic management In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds) Comprehensive textbook of genitourinary oncology. Lippincott Williams & Wilkins, Philadelphia, pp 367–376.Google Scholar
  15. 15.
    Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52: 594–601.PubMedCrossRefGoogle Scholar
  16. 16.
    Kroft SH, Oyasu R (1994) Biology of disease—urinary bladder cancer: mechanisms of development and progression. Lab Invest 71: 158–174.PubMedGoogle Scholar
  17. 17.
    IARC (1979) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Supplement 1. Chemicals and industrial processes associated with cancer in humans. International Agency for Research on Cancer, Lyon.Google Scholar
  18. 18.
    US DHEW (1979) Smoking and health: a report of the Surgeon General. PHS Publ 79-50066. Department of Health, Education and Welfare, Washington, DC.Google Scholar
  19. 19.
    Kadlubar FF, Miller JA, Miller EC (1977) Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxyarylamines in relation to urinary bladder carcinogenesis. Cancer Res 37: 805–814.PubMedGoogle Scholar
  20. 20.
    Bladder Cancer (1981) In: Skrabanek P, Walsh, A (eds) UICC technical report series, vol 60. UICC, Geneva, pp 118–143.Google Scholar
  21. 21.
    Dominick MA, White MR, Sanderson TP, Van Fleet T, Cohen SM, Arnold LE, Cano M, Tannehill-Gregg S, Moehlenkamp JD, Waites CR, Schilling BE (2006) Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 34: 903–920.PubMedCrossRefGoogle Scholar
  22. 22.
    Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick BG (2000) Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 88: 1663–1670.PubMedCrossRefGoogle Scholar
  23. 23.
    Krogh J, Kvist E, Rye B (1991) Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences. Br J Urol 67: 32–36.PubMedCrossRefGoogle Scholar
  24. 24.
    Charbit L, Gendreau MC, Mee S, Cukier J (1991) Tumors of the upper urinary tract: 10 years of experience. J Urol 146: 1243–1246.PubMedGoogle Scholar
  25. 25.
    Holmang S, Johansson SL (2006) Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol 175: 69–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Lynch HT, Taylor RJ, Lynch JF, Knezetic JA, Barrows A, Fodde R, Wijnen J, Wagner A (2003) Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: molecular genetic, diagnostic, and management implications. Am J Gastroenterol 98: 664–670.PubMedCrossRefGoogle Scholar
  27. 27.
    Kang C-H, Yu T-J, Hsieh H-H, Yang JW, Shu K, Huang C-C, Chiang P-H, Shiue Y-L (2003) The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 98: 1620–1626.PubMedCrossRefGoogle Scholar
  28. 28.
    Kakizoe T, Fujita J, Murase T, Matsumoto K, Kishi K (1980) Transitional cell carcinoma of the bladder in patients with renal pelvic and ureteral cancer. J Urol 124: 17–19.PubMedGoogle Scholar
  29. 29.
    Takahashi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Kato T, Ogawa O, Habuchi T (2001) Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J Urol 165: 672–677.PubMedCrossRefGoogle Scholar
  30. 30.
    Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Yoshida O (1998) Clonal and chronologic genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 58: 5835–5841.PubMedGoogle Scholar
  31. 31.
    Kirkali Z, Tuzel E (2003) Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol 47: 155–169.PubMedCrossRefGoogle Scholar
  32. 32.
    Amar AD, Das S (1985) Upper urinary tract transitional cell carcinoma in patients with bladder carcinoma and associated vesicoureteral reflux. J Urol 133: 468–471.PubMedGoogle Scholar
  33. 33.
    De Torres Mateos JA, Banus Gassol JM, Palou Redorta J, Morote Robles J (1987) Vesicorenal reflux and upper urinary tract transitional cell carcinoma after transurethral resection of recurrent superficial bladder carcinoma. J Urol 138: 49–51.PubMedGoogle Scholar
  34. 34.
    Palou J, Farina LA, Villavicencio H, Vicente J (1992) Upper tract urothelial tumor after transurethral resection for bladder tumor. Eur Urol 21: 110–114.PubMedGoogle Scholar
  35. 35.
    Mukamel E, Nissenkorn I, Glanz I, Vilcovsky E, Servadio C (1985) Upper tract tumours in patients with vesico-ureteral reflux and recurrent bladder tumours. Eur Urol 11: 6–8.PubMedGoogle Scholar
  36. 36.
    Miller EB, Eure GR, Schellhammer PF (1993) Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. Urology 42: 26–30.PubMedCrossRefGoogle Scholar
  37. 37.
    Herr HW, Whitmore WF Jr (1987) Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. J Urol 138: 292–294.PubMedGoogle Scholar
  38. 38.
    Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Huguet-Perez J, Vicente-Rodriguez J (2000) Upper urinary tract tumors after primary superficial bladder tumors; prognostic factors and risk group. J Urol 164: 1183–1187.PubMedCrossRefGoogle Scholar
  39. 39.
    Shinka T, Uekado Y, Aoshi H, Hirano A, Ohkawa T (1988) Occurrence of uroepithelial tumors of the upper urinary tract after the initial diagnosis of bladder cancer. J Urol 140: 745–748.PubMedGoogle Scholar
  40. 40.
    Solsona E, Iborra I, Ricos JV, Dumont R, Casanova JL, Calabuig C (1997) Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management. Urology 49: 347–352.PubMedCrossRefGoogle Scholar
  41. 41.
    Hurle R, Losa A, Manzetti A, Lembo A (1999) Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology 53: 1144–1148.PubMedCrossRefGoogle Scholar
  42. 42.
    Canales BK, Anderson JK, Premoli J, Slaton JW (2006) Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage Ta bladder cancer. J Urol 175: 74–77.PubMedCrossRefGoogle Scholar
  43. 43.
    Schwartz CB, Bekirov H, Melman A (1992) Urothelial tumors of upper tract following treatment of primary bladder transitional cell carcinoma. Urology 40: 509–511.PubMedCrossRefGoogle Scholar
  44. 44.
    Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67: 1216–1223.PubMedCrossRefGoogle Scholar
  45. 45.
    Schwalb DA, Herr HW, Sogani PC, Russo P, Sheinfeld J, Fair WR (1992) Upper tract disease following intravesical BCG for superficial bladder cancer: five year follow-up. J Urol 147(suppl):273A.Google Scholar
  46. 46.
    Ratliff TL (1991) Bacillus Calmette-Guerin (BCG): mechanism of action in superficial bladder cancer. Urology 37(suppl 5): 8–11.PubMedCrossRefGoogle Scholar
  47. 47.
    Malkowicz SB, Skinner DG (1990) Development of upper tract carcinoma after cystectomy for bladder carcinoma. Urology 35: 20–22.CrossRefGoogle Scholar
  48. 48.
    Hastie KJ, Hamdy FC, Collins MC, Williams JL (1991) Upper tract tumours following cystectomy for bladder cancer: is routine intravenous urography worthwhile? Br J Urol 67: 29–31.PubMedCrossRefGoogle Scholar
  49. 49.
    Mufti GR, Gove JRW, Riddle PR (1988) Nephroureterectomy after radical cystectomy. J Urol 139: 588–589.PubMedGoogle Scholar
  50. 50.
    Huguet-Perez J, Palou J, Millan-Rodriguez F, Salvador-Bayarri J, Villavicencio-Mavrich H, Vicente-Rodriguez J (2001) Upper tract transitional cell carcinoma following cystectomy for bladder cancer. Eur Urol 40: 318–323.PubMedCrossRefGoogle Scholar
  51. 51.
    Zincke H, Garbeff PJ, Beahrs JR (1984) Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer. J Urol 131: 50–52.PubMedGoogle Scholar
  52. 52.
    Schellhammer PF, Whitmore WF Jr (1976) Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 115: 56–60.PubMedGoogle Scholar
  53. 53.
    Balaji KC, McGuire M, Grotas J, Grimaldi G, Russo P (1999) Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation. J Urol 162: 1603–1606.PubMedCrossRefGoogle Scholar
  54. 54.
    Kenworthy P, Tanguay S, Simon T, Dinney CP (1996) The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol 155: 501–503.PubMedCrossRefGoogle Scholar
  55. 55.
    Johansson S, Angervall L, Bengtsson U, Wahlqvist L (1976) A clinicopathologic and prognostic study of epithelial tumors of the renal pelvis. Cancer 37: 1376–1383.PubMedCrossRefGoogle Scholar
  56. 56.
    Davis BW, Hough AJ, Gardner WA (1987) Renal pelvic carcinoma: morphological correlates of metastatic behavior. J Urol 137: 857–861.PubMedGoogle Scholar
  57. 57.
    Huben RP, Mounzer AM, Murphy GP (1988) Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 62: 2016–2020.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Personalised recommendations